Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MEDI0382 (Cotadutide) Dose-Ranging Study in Japanese Patients with T2DM and Obesity
NCT03645421Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Aug 2018
- Primary completion
- Jan 2019
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of cotadutide in type 2 diabetes mellitus (T2DM) and obesity (4 arms), sponsored by AstraZeneca. Primary endpoints: Mean Change From Baseline in 24-Hour Heart Rate at Day 48, Mean Change From Baseline in 24-Hour Systolic and Diastolic Blood Pressure at Day 48 and 4 more. Started Aug 2018; status: completed.
02
Drugs
cotadutide
03
Conditions
type 2 diabetes mellitus (T2DM)obesity
Beyond the preview
Go deeper on NCT03645421.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03645421.